A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing Thursday on how the agency’s bureaucracy affects innovation, with one witness testifying that ...

A new preclinical model offers a unique platform for studying the Parkinson's disease process and suggests a relatively easy method for detecting the disease in people. A new preclinical model offers ...

Researchers have developed a diagnostic panel that identifies cognitive decline by analyzing how blood proteins fold. This ...

For decades, medical understanding of Parkinson’s disease focused exclusively on the brain, specifically the death of dopamine-producing neurons that control movement. This narrow view shaped ...

Ruthie Davi, vice president of statistics and regulatory innovation at Medidata, highlights the value of technology in rare ...

Beta-amyloid plaques are considered a hallmark of Alzheimer’s disease, but they’re not the sole cause of the disease and its symptoms. Alzheimer’s is a complicated disease that experts are still ...

Please provide your email address to receive an email when new articles are posted on . Ianalumab bested placebo in ESSDAI score at 48 weeks among patients with Sjögren’s disease. Monthly ianalumab ...

Plus, when to see a doctor.